Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 334

Similar articles for PubMed (Select 12351470)

1.

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI.

Diabetes Care. 2002 Oct;25(10):1737-43.

PMID:
12351470
2.
4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.
6.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

9.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
11.
12.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
13.
14.

[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].

Scheen AJ.

Rev Med Liege. 2007 Jan;62(1):48-52. French.

PMID:
17343130
16.

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D; Glyburide/Metformin Initial Therapy Study Group.

Diabetes Obes Metab. 2002 May;4(3):201-8. Erratum in: Diabetes Obes Metab. 2002 Jul;4(4):286..

PMID:
12047399
17.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.

J Intern Med. 2005 Jan;257(1):100-9.

PMID:
15606381
18.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
19.

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP.

Diabetologia. 2005 Sep;48(9):1726-35. Epub 2005 Jul 16.

PMID:
16025252
20.

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.

Diabetes Obes Metab. 2006 Mar;8(2):156-63.

PMID:
16448519
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk